Western Blot: NGFI-B alpha/Nur77/NR4A1 Antibody [NB100-56745] - Analysis of Nur77 (Nak-1) in 15 ugs of NIH3T3 cell lysate using Nur77 antibody at 1:500 dilution
Immunocytochemistry/ Immunofluorescence: NGFI-B alpha/Nur77/NR4A1 Antibody [NB100-56745] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. ...read more
Immunocytochemistry/ Immunofluorescence: NGFI-B alpha/Nur77/NR4A1 Antibody [NB100-56745] - Antibody tested in Jurkat cells at a 1:50 dilution against DyLight 488 (Green). Alpha tubulin and nuclei were counterstained ...read more
Chromatin Immunoprecipitation: See Lee et al (2009). ICC/IF: See Chintharlapalli et al (2005) Immunoprecipitation: See Ferlini et al (2009). Use in Immunohistochemistry reported in scientific literature (PMID: 31115481).
Read 3 Reviews rated 4.7 using NB100-56745 in the following applications:
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.05% Sodium Azide
Protein G purified
Alternate Names for NGFI-B alpha/Nur77/NR4A1 Antibody
Early response protein NAK1
growth factor-inducible nuclear protein N10
Nuclear hormone receptor NUR/77
nuclear receptor subfamily 4 group A member 1
nuclear receptor subfamily 4, group A, member 1
Orphan nuclear receptor HMR
Orphan nuclear receptor TR3
steroid receptor TR3
Testicular receptor 3
TR3 orphan receptor
Nak1 is a member of the steroid/thyroid hormone receptor superfamily. The gene for Nak-1 is induced rapidly by androgens/growth factors and may have functions related to cell proliferation, differentiation and apoptosis (1). Liu et al (2) have demonstrated that mouse nur77 is necessary for induced apoptosis in T-cell hybridomas and can also be induced during early mitogenesis.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for NGFI-B alpha/Nur77/NR4A1 Antibody (NB100-56745). (Showing 1 - 1 of 1 FAQs).
We have a customer who would like to use NB100-56745 in ChIP experiments. However, they would like to see the data that suggests this antibody could be used in ChIP, which we do not have. Could you pass along that data? Thanks!
Product NB100-56745 is a new product added to our catalog from our recent acquisition with Imgenex. They had verified the use of ChIP with this product from the following publication: p21 expression is induced by activation of nuclear nerve growth factor-induced Ba (Nur77) in pancreatic cancer cells. Lee S-O, S Chintharlapalli, S Liu, S Papineni, SD Cho, K Yoon, S Safe. Mol Cancer Res 7:1169-1178 (2009). IF: Fig 2 (Panc1 cells) WB: Figs 3C and 4B (Panc1 or L3.6pl cells transfected with scrambled or Nur77 siRNA); Figs 6A, 6D (Panc1 cells) ChIP: Fig 5 (Panc1 cells) Note: Nur77 was detected in the nuclear, but not the cytoplasmic fraction of Panc1 cells by WB (Fig 6D). Note: The Nur77 IMG-528 antibody was Nur77 siRNA transfected validated by western blot. Nur77 siRNA, but not scrambled siRNA reduced the intensity of the WB signal in PANC1 and L3.6pi cells (Figs 3C, 4B).
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.